Erratum to: High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children’s Oncology Group

Author details Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D2-190, Seattle, WA 98109-1024, USA. Department of Biostatistics, University of Southern California, Los Angeles, CA, USA. Children’s Oncology Group, Monrovia, CA, USA. Molecular Pharmacology and Chemistry Program, Sloan Kettering Institute, New York, NY, USA. Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Weill Medical College of Cornell University, New York, NY, USA. Department of Pathology, St. Jude Children’s Research Hospital, Memphis, TN, USA. Department of Laboratory Medicine and Pathology, University of Minnesota Cancer Center, Minneapolis, MN, USA. Division of Hematology-Oncology, Children’s Mercy Hospitals and Clinics, Kansas City, MO, USA. Department of Pediatrics, University of Washington, Seattle, WA, USA. Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA. Department of Epidemiology, University of Washington, Seattle, WA, USA.